Alpha-fetoprotein and human chorionic gonadotrophin-beta as prognostic markers in neuroendocrine tumour patients. 2008

T Shah, and R Srirajaskanthan, and M Bhogal, and C Toubanakis, and T Meyer, and A Noonan, and C Witney-Smith, and T Amin, and P Bhogal, and N Sivathasan, and B Warner, and D Hochhauser, and M E Caplin
Neuroendocrine Tumour Unit, Centre for Gastroenterology, Royal Free Hospital, Pond Street, London, NW3 2QG, UK.

Serum chromogranin A is the most useful general and prognostic tumour marker available for neuroendocrine tumour (NET) patients. The role of other tumour markers is less clear. In order to determine the diagnostic and prognostic value of serum alpha-fetoprotein (AFP) and human chorionic gonadotrophin-beta (hCGbeta) in NETs, a database containing biochemical, histological, and survival data on 360 NET patients was constructed. This data was statistically assessed, using Statistical Package for the Social Sciences, to determine the utility of commonly measured tumour markers with particular emphasis on AFP and hCGbeta. Alpha-fetoprotein and hCGbeta were raised in 9.5 and 12.3% of patients respectively and jointly raised in 9.1% of patients in whom it was measured. Alpha-fetoprotein levels associated strongly and positively with tumour grade, serum CgA and hCGbeta levels, and worse survival. Human chorionic gonadotrophin-beta levels also associated strongly and positively with serum CgA and AFP levels, and worsening survival. Alpha-fetoprotein and hCGbeta are elevated in high-grade NETs, with a rapidly progressive course and poorer survival. They also correlate with chromogranin-A, which is known to be a marker of tumour burden and to have prognostic value. Thus AFP and hCGbeta are clinically important in NETs and when elevated are poor prognostic markers.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000509 alpha-Fetoproteins The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life. alpha-Fetoprotein,alpha Fetoprotein,alpha Fetoproteins
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses

Related Publications

T Shah, and R Srirajaskanthan, and M Bhogal, and C Toubanakis, and T Meyer, and A Noonan, and C Witney-Smith, and T Amin, and P Bhogal, and N Sivathasan, and B Warner, and D Hochhauser, and M E Caplin
April 1999, Drugs,
T Shah, and R Srirajaskanthan, and M Bhogal, and C Toubanakis, and T Meyer, and A Noonan, and C Witney-Smith, and T Amin, and P Bhogal, and N Sivathasan, and B Warner, and D Hochhauser, and M E Caplin
July 1979, Minnesota medicine,
T Shah, and R Srirajaskanthan, and M Bhogal, and C Toubanakis, and T Meyer, and A Noonan, and C Witney-Smith, and T Amin, and P Bhogal, and N Sivathasan, and B Warner, and D Hochhauser, and M E Caplin
August 2000, BMJ (Clinical research ed.),
T Shah, and R Srirajaskanthan, and M Bhogal, and C Toubanakis, and T Meyer, and A Noonan, and C Witney-Smith, and T Amin, and P Bhogal, and N Sivathasan, and B Warner, and D Hochhauser, and M E Caplin
December 1978, British journal of urology,
T Shah, and R Srirajaskanthan, and M Bhogal, and C Toubanakis, and T Meyer, and A Noonan, and C Witney-Smith, and T Amin, and P Bhogal, and N Sivathasan, and B Warner, and D Hochhauser, and M E Caplin
January 1981, International journal of biological research in pregnancy,
T Shah, and R Srirajaskanthan, and M Bhogal, and C Toubanakis, and T Meyer, and A Noonan, and C Witney-Smith, and T Amin, and P Bhogal, and N Sivathasan, and B Warner, and D Hochhauser, and M E Caplin
August 2020, QJM : monthly journal of the Association of Physicians,
T Shah, and R Srirajaskanthan, and M Bhogal, and C Toubanakis, and T Meyer, and A Noonan, and C Witney-Smith, and T Amin, and P Bhogal, and N Sivathasan, and B Warner, and D Hochhauser, and M E Caplin
January 2003, BJOG : an international journal of obstetrics and gynaecology,
T Shah, and R Srirajaskanthan, and M Bhogal, and C Toubanakis, and T Meyer, and A Noonan, and C Witney-Smith, and T Amin, and P Bhogal, and N Sivathasan, and B Warner, and D Hochhauser, and M E Caplin
October 2006, Molecular human reproduction,
T Shah, and R Srirajaskanthan, and M Bhogal, and C Toubanakis, and T Meyer, and A Noonan, and C Witney-Smith, and T Amin, and P Bhogal, and N Sivathasan, and B Warner, and D Hochhauser, and M E Caplin
June 2003, Prenatal diagnosis,
T Shah, and R Srirajaskanthan, and M Bhogal, and C Toubanakis, and T Meyer, and A Noonan, and C Witney-Smith, and T Amin, and P Bhogal, and N Sivathasan, and B Warner, and D Hochhauser, and M E Caplin
November 1980, Histopathology,
Copied contents to your clipboard!